Across TCGA pan-cancer cohorts, GSG1L2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of GSG1L2’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GSG1L2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GSG1L2 is over-expressed in tumor.
KIRC and LUSC are the cancer types where GSG1L2 tumor–normal differential expression is most reproducible.